Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor

NCT ID: NCT05469984

Last Updated: 2025-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-25

Study Completion Date

2025-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized prospective trial aimed to compare 2 prophylactic antibiotic regiment (ampicillin alone versus ampicillin plus gentamycin) in term prolonged pre-labor rupture of membrane and in preterm deliveries and examine related obstetrical outcome and infectious morbidity

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maternal peripartum fever is a common complication of pregnancy and postpartum period associated with potentially serious obstetrical outcomes and infectious morbidity. Peripartum infections includes intrapartum intraamniotic infection (IAI) and postpartum endometritis. Both are caused by polymicrobial bacterial infection. Increased latency period from rupture of membranes (ROM) until delivery is a common risk factor. Another risk factor is pre-term delivery.

This randomized prospective trial aimed to compare 2 prophylactic antibiotic regiment (ampicillin alone versus ampicillin plus gentamycin) in term prolonged pre-labor rupture of membrane and in preterm deliveries and examine related obstetrical outcome and infectious morbidity.

Primary outcome-peripartum infections- chorioamnionitis, endometritis and surgical site infection secondary outcome- obstetrical outcome- mode of delivery, Apgar score, cord blood pH, peripartum fever, maternal length of admission, postpartum maternal antibiotic treatment, Surface swab cultures were obtained from the placenta, amnion and umbilical cord (birth cultures) and uterine swab cultures, maternal blood culture, placental histologic evaluation neonatal outcomes-NICU admission, length of admission, neonatal morbidity-ventilation support, early neonatal sepsis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Labor With Preterm Delivery Premature Rupture of Membranes Prolonged

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

women with prolonged premature rupture of membrane\>18 h or women in preterm delivery will be randomized to receive one of two prophylactic antibiotic treatment
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

women with term prolonged>18h rupture of membrane

women with term prolonged \>18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery

Group Type ACTIVE_COMPARATOR

Ampicillin Only Product

Intervention Type DRUG

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

ampicillin plus gentamicin

Intervention Type DRUG

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

women with preterm labor

women with term prolonged \>18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery plus IV gentamicin 5 mg/kg every 24 hours

Group Type ACTIVE_COMPARATOR

Ampicillin Only Product

Intervention Type DRUG

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

ampicillin plus gentamicin

Intervention Type DRUG

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ampicillin Only Product

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

Intervention Type DRUG

ampicillin plus gentamicin

women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

* GBS carrier
* preterm premature rupture of membrane for conservative treatment
* intra-uterine fetal death fetal major anomaly
* drug allergy for the antibiotic in use in this study
* women receiving antibiotic treatment for other infection such as urinary tract infection
Minimum Eligible Age

18 Years

Maximum Eligible Age

48 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Western Galilee Hospital-Nahariya

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Maya Wolf

Director- Fetal Maternal Medicine Unit

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Galil Medical Center

Nahariya, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maya Wolf, MD

Role: CONTACT

972-50-7887800

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maya Wolf, MD

Role: primary

972-507887800

References

Explore related publications, articles, or registry entries linked to this study.

Apantaku O, Mulik V. Maternal intra-partum fever. J Obstet Gynaecol. 2007 Jan;27(1):12-5. doi: 10.1080/01443610601016644.

Reference Type BACKGROUND
PMID: 17365450 (View on PubMed)

Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection. Obstet Gynecol. 2017 Aug;130(2):e95-e101. doi: 10.1097/AOG.0000000000002236.

Reference Type BACKGROUND
PMID: 28742677 (View on PubMed)

Kachikis A, Eckert LO, Walker C, Bardaji A, Varricchio F, Lipkind HS, Diouf K, Huang WT, Mataya R, Bittaye M, Cutland C, Boghossian NS, Mallett Moore T, McCall R, King J, Mundle S, Munoz FM, Rouse C, Gravett M, Katikaneni L, Ault K, Klein NP, Roberts DJ, Kochhar S, Chescheir N; Brighton Collaboration Chorioamnionitis Working Group. Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019 Dec 10;37(52):7610-7622. doi: 10.1016/j.vaccine.2019.05.030. No abstract available.

Reference Type BACKGROUND
PMID: 31783982 (View on PubMed)

Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, Jun JK. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001 Nov;185(5):1130-6. doi: 10.1067/mob.2001.117680.

Reference Type BACKGROUND
PMID: 11717646 (View on PubMed)

Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol. 1996 Aug;175(2):304-9; discussion 309-10. doi: 10.1016/s0002-9378(96)70139-4.

Reference Type BACKGROUND
PMID: 8765246 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0103-22-NHR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.